AstraZeneca’s Soriot Dismisses Any Pfizer Vaccine ‘Envy’ Amid Buoyant Q2 Results
Growth Buoyant Despite Vaccine Complications
The UK company has raised its forecasts for 2021 after a better-than-expected Q2, even though Vaxzevria remains a very mixed blessing.